DOCSLIB.ORG

وﺣدة اﻟﻘﯾﺎس اﻟﻣﻼﺣظﺎت اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ 2799663 12484 52046 30340 0 7101 0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
وﺣدة اﻟﻘﯾﺎس اﻟﻣﻼﺣظﺎت اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ 2799663 12484 52046 30340 0 7101 0 وﺣدة NATIONAL اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ اﻟﻣﻼﺣظﺎت اﻟﻘﯾﺎس CODE 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 01-AA0-004 Digoxin 250 mcg scored Tablet tab 2799663 01-AA0-005 Digoxin 50mcg /ml PG Elixir ( 60ml ) bottle 12484 01-AA0-006 Digoxin 250 mcg/ml inj (2ml) Ampoule amp 52046 01-AA0-003 Digoxin 125 mcg Tablet tab 30340 1AB PHOSPHODIESTERASE INHIBITORS 0 ﯾؤﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎر ﻗﺎﺋﻣﺔ ادوﯾﺔ اﻟﺗﺧدﯾر Milrinone as lactate 1mg/1ml Injection 10ml 17-000-050 amp amp 7101 1B DIURETICS 0 اﻟﻣراﻛز اﻟﻣﺗﺧﺻﺻﺔ ﻻﻣراض اﻟﻘﻠب Bumetanide 1 mg Tablet (very limited tab 01-B00-002 amount) (very limited amount) 232812 Furosemide IV ,IM/or slow IV ,IM inj amp 01-B00-005 20mg/2ml Ampoule 5798440 01-B00-007 Furosemide 40mg Tablet tab 5083506 01-B00-013 Hydrochlorothiazide 50mg scroed Tablet tab 8709833 09-D00-021 Mannitol 20% I.V. infusion 500ml bottle 182436 01-B00-016 Spironolactone 25mg Tablet tab 617494 01-B00-017 Spironolactone 100mg Tablet tab 291566 01-B00-012 Hydrochlorothiazide 25mg Tablet tab 237325 Furosemide oral solution 20mg/5 ml or 01-B00-021 4mg/1ml 6084 01-B00-022 Spironolactone 5 mg / 5 ml oral suspension 2665 BETA-ADRENOCEPTER BLOCKING 1C DRUGS 0 01-C00-003 Atenolol 100mg Tablet tab 16868482 01-C00-004 Atenolol 50mg Tablet or (scored tab) tab 8481145 (limited amount) tab 01-C00-008 Carvedilol 6.25mg Tablet (limited amount) 2081699 01-C00-010 Carvedilol 25mg Tablet (limited amount) tab (limited amount) 1389247 (limited amount) "اﻟﻣراﻛز اﻟﺗﺧﺻﺻﯾﺔ ﻟﻠﻘﻠب واﯾﺿﺎ (CCU) اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺗﻌﻠﯾﻣﯾﺔ واﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﻌﺎﻣﺔ اﻟﺗﻲ vial ﺗﺗﺿﻣن اﻗﺳﺎم اﻟﻌﻧﺎﯾﺔ اﻟﻘﻠﺑﯾﺔ اﻟﻣرﻛزة وﯾؤﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎر (Esmolol Hcl 10mg/ml I.V. infusion (10ml 6880 اﺳﺗﺧداﻣﮫ ﻓﻲ اﻟﺗﺧدﯾر (01-C00-011 Vial (CCU) (limited amount وﯾؤﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎر اﺳﺗﺧداﻣﮫ ﻓﻲ اﻟﺗﺧدﯾر (Propranolol Hcl 1mg/ml slow IV inj (1ml) limited amp 01-C00-023 Ampoule (limited amount) (amount 26735 PDF created with pdfFactory Pro trial version www.pdffactory.com وﺣدة NATIONAL اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ اﻟﻣﻼﺣظﺎت اﻟﻘﯾﺎس CODE Propranolol Hcl 40mg Tablet (or scored tab 01-C00-025 Tablet) 5988470 01-C00-024 Propranolol Hcl 10mg Tablet tab 777952 01-C00-036 Atenolol I.V or I.V infusion 500 microgram/ ml amp (10ml-Amp) 3760 اﺣﺗﯾﺎج واﺣد Labetalol inj. 5mg/ml (20ml) Amp (limited amp limited amount) 5810) وﺗﺳﺗﺧدم اﯾﺿﺎ" ﻣن (01-C00-012 amount 0 ﻗﺑل وﺣدات اﻟﺗﺧدﯾر 01-C00-040 Labetalol inj. 5mg/ml (20ml) vial vial وﺗﺳﺗﺧدم اﯾﺿﺎ" ﻣن ﻗﺑل وﺣدات اﻟﺗﺧدﯾر (Metoprolol tartrate 1mg/1ml I.V. inj (5ml 01-C00-017 Ampoule amp 36507 1D ANTI-ARRHYTHMIC DRUGS 0 20344 اﺣﺗﯾﺎج واﺣد 01-D00-027 Adenosine inj. 3mg/ml (2ml) Vial vial 01-D00-028 Adenosine inj. 3mg/ml (2ml) Ampoule amp 0 ﯾؤﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎر ﺿﻣن ﻗﺎﺋﻣﺔ (Amiodarone Hcl inj 50mg/ml (3ml) Ampoule (limited amount amp 134928 اﻟﺗﺧدﯾر (01-D00-001 (limited amount 01-D00-002 Amiodarone Hcl 200mg Tablet tab 396024 ﻟﻠﻣﺳﺗﺷﻔﯾﺎت اﻟﺗﺧﺻﺻﯾﺔ (Mexiletine Hcl 25mg/ml I.V.,I.V.infusion .inj (limited amount amp ﻟﻠﻣﺳﺗﺷﻔﯾﺎت(10ml) Ampoule) (limited amount) 1150 اﻟﺗﺧﺻﺻﯾﺔ 01-D00-013 01-D00-019 Propafenon Hcl 150mg Tablet tab 12990 Verapamil Hcl inj 2.5mg/ml, (2ml) Ampoule amp 01-D00-022 slow I.V. inj 30464 01-D00-024 Verapamil Hcl 80mg Tablet tab 86747 ﯾدرج ﺿﻣن ﻗواﺋم اﻟﺗﺧدﯾر ﯾﺳﺗﺧدم ﻓﻲ وﺣدة اﻟﻌﻧﺎﯾﺔ ) 01-D00-034 Lignocaine Hcl 2% 20mg /ml 2ml Ampoule amp 56590 اﻟﻣرﻛزة (CCU ﯾﺳﺗﺧدم ﻓﻲ اﻟﻣراﻛز اﻟﺗﺧﺻﺻﯾﺔ (Flecainide acetate inj 10mg/ml (15ml) (limited amount Ampoul ) (Only in the heart specialised amp 2060 ﻟﻠﻘﻠب ﻓﻘط (01-D00-035 center) (limited amount 01-D00-006 Disopyramide 250mg modified release or tab (s/r) Tablet 28850 01-D00-007 Disopyramide inj 10mg/ml (5ml) amp amp hospital only (hospital only) 1574 ANTI-HYPERTENSIVE DRUGS * ﻣﻼﺣظﺔ .1ﯾﻧﺗﺧب اﺣدھﻣﺎ ﻋﻠﻰ ﻗﺎﻋدة اﻗل اﻻﺳﻌﺎر : Sartans ﺣول ﯾﺻرف ﺣﺳب اﻟﺿواﺑط اﻟواردة ﻓﻲ ﻗرار اﻟﮭﯾﺋﺔ ﺟﻠﺳﺔ ٤٨٥ 2- 0 . ﻓﻲ ٢٠٠٤/١٢/١٤ 1E 01-E00-003 Captopril 25mg Tablet tab 30343217 01-E00-004 Captopril 50mg Tablet tab 20307361 tab 01-E00-006 Candesartan cilexetil 8mg Scored Tablet * 9106983 PDF created with pdfFactory Pro trial version www.pdffactory.com وﺣدة NATIONAL اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ اﻟﻣﻼﺣظﺎت اﻟﻘﯾﺎس CODE tab 01-E00-060 Candesartan cilexetil 16mg Tablet * 8970142 01-E00-013 Enalapril maleate 20mg Scored Tablet tab 1192964 (limited amount) ﯾﺧﺗﺎر اﺣدھﻣﺎ ﻋﻠﻰ ﻗﺎﻋدة اﻗل اﻻﺳﻌﺎر ﻣـــﻊ Hydralazine Hcl 20mg I.V. Infusion per amp 01-E00-014 Ampoule (limited amount) Methyldopate inj 57685 ( Limited amount) ﯾﺧﺗﺎر اﺣدھﻣﺎ ﻋﻠﻰ ﻗﺎﻋدة اﻗل اﻻﺳﻌﺎر ﻣــﻊ Methyldopate 50mg/ml,inj. (5ml) Ampoule amp 01-E00-023 (Limited amount ) Hydralazine I.V . Infusion 22258 (limited amount) tab 01-E00-024 Methyldopa 250mgTablet (limited amount) 3455169 Phentolamine mesylate inj 10mg/ml, (1ml) (very limited amount) amp 01-E00-031 Ampoule (very limited amount) 805 01-E00-075 Terazosin as Hcl 5mg Tablet tab 136276 tab 01-E00-020 Losartan potassium 50mg Tablet * 8160905 01-E00-078 tab Losartan potassium 100mg Tablet * 8008451 01-E00-067 Valsartan 80mg Tablet tab 8441277 0 اﺣﺗﯾﺎج واﺣد * 01-E00-083 Valsartan 80mg cap cap 01-E00-068 Valsartan 160mg Tablet tab 8291217 0 اﺣﺗﯾﺎج واﺣد * 01-E00-084 Valsartan 160mg cap cap 01-E00-058 Telmisartan 40mg Tablet tab * 8222861 01-E00-059 Telmisartan 80mg Tablet tab * 8188909 01-E00-074 Terazosin as Hcl 2mg Scored Tablet tab 55273 اﺣﺗﯾﺎج واﺣد (very limited amount ) وﯾؤﺧذ Sodium nitroprusside 50mg I.V. infusion 01-E00-049 Ampoule with solvent amp 7351 Sodium nitroprusside 50mg I.V. infusion Vial 0 ﺑﻧظر اﻻﻋﺗﺑﺎر اﺳﺗﺧداﻣﮫ ﻓﻲ اﻟﺗﺧدﯾر 01-E00-048 with solvent vial 01-E00-088 Bosentan as monohydrate 125mg tablet tab 9850 captopril (liqiud ) :6.25mg/5ml dos 100 mcg / 01-E00-087 Kg Max. 6.25mg. bottle 3665 1F VASODILATORS 0 ( اﺣﺗﯾﺎج واﺣد) tab 3980542 ﯾﻛون ﺑﻧﺳﺑﺔ ٣/٢ ﻣن اﻻﺣﺗﯾﺎج اﻟﻛﻠﻲ ﻣﻊ اﻟﻣﺎدة 01-F00-002 Amlodipine (as besylate) 5mg Scored Tablet 01-F00-065 Amlodipine (as besylate) 5mg Capsule cap (Amlodipine (as besylate) 2.5mg Tablet) 0 ﯾﻛون ﺑﻧﺳﺑﺔ ٣/١ ﻣن اﻻﺣﺗﯾﺎج اﻟﻛﻠﻲ ﻣﻊ اﻟﻣﺎدة Amlodipine (as besylate) 5mg Scored) 01-F00-001 Amlodipine (as besylate) 2.5mg Tablet (or plain Tablet 1341719 PDF created with pdfFactory Pro trial version www.pdffactory.com وﺣدة NATIONAL اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ اﻟﻣﻼﺣظﺎت اﻟﻘﯾﺎس CODE 544048 اﺣﺗﯾﺎج واﺣد 01-F00-009 Diltiazem Hcl 90mg (s/r) Capsule cap 01-F00-010 Diltiazem Hcl 90mg (s/r) Tablet tab 0 اﺣﺗﯾﺎج واﺣد (Diltiazem Hcl 25mg I.V.Infusion Vial (limited (limited amount vial 2245 ﻓﻲ ﻣراﻛز اﻟﻘﻠب (01-F00-021 amount Diltiazem Hcl 25mg I.V.Inj Vial (limited vial 0 ﻓﻲ ﻣراﻛز اﻟﻘﻠب ﻓﻲ ﻣراﻛز اﻟﻘﻠب (01-F00-022 amount tab 01-F00-024 Glyceryl trinitrate 0.5mg sublingual Tablet 23702253 340482 (اﺣﺗﯾﺎج واﺣد ) 01-F00-035 Isosorbide dinitrate 20mg (s/r) Tablet tab 01-F00-064 Isosorbide dinitrate 20mg retard Capsule cap 0 12109398 (اﺣﺗﯾﺎج واﺣد ) 01-F00-038 Isosorbide mononitrate 10mg Tablet tab 01-F00-034 Isosorbide dinitrate 10mg Tablet tab 0 Nimodipine 30mg Tabet (very limited (very limited amount) tab 136556 ﻣراﻛز اﻟﺟﻣﻠﺔ اﻟﻌﺻﺑﯾﺔ وردھﺎت اﻻﻣراض اﻟﻌﺻﺑﯾﺔ (01-F00-060 amount Nimodipine 200mcg/ml I.V. infusion (50ml) (very limited amount) vial 1149 ﻣراﻛز اﻟﺟﻣﻠﺔ اﻟﻌﺻﺑﯾﺔ وردھﺎت اﻻﻣراض اﻟﻌﺻﺑﯾﺔ (01-F00-061 Vial (very limited amount (اﺣﺗﯾﺎج واﺣد ) Nifedipine 20mg (s/r) or retard Capsule cap 01-F00-055 (60% of the need) 1922699 Nifedipine 20mg (s/r) or retard Tablet tab 01-F00-056 (60% of the need) 0 limited amount ) 60287) اﺣﺗﯾﺎج واﺣد ﻓﻲ ﺣﺎﻟﺔ ﻋدم ﺗوﻓر 01-F00-073 Glyceryl trinitrate 5mg/ml(5ml )Ampoule اﺣد واﻟﺗرﻛﯾزﯾن ﯾﺗم ﺗوﻓﯾر اﻟﺗرﻛﯾز اﻻﺧر وﯾؤﺧذ ﺑﻧظر amp 0 اﻻﻋﺗﺑﺎر اﺳﺗﺧداﻣﮫ ﺿﻣن ﻗواﺋم اﻟﺗﺧدﯾر 01-F00-069 Glyceryl trinitrate 1mg/1ml (10ml) Ampoule Glyceryl trinitrate 5mg patches releasing 01-F00-026 approx.5mg/24 hours patch 54665 Glyceryl trinitrate 10mg patches releasing 01-F00-027 approx.10mg/24 hours patch 79275 Glyceryl trinitrate 15mg patches releasing 01-F00-028 approx.15mg/24 hours 55975 اﺣﺗﯾﺎج واﺣد 01-F00-053 Nifedipine 10mg (s/r or retard) Capsule cap (40% of the need) 1274133 01-F00-054 Nifedipine 10mg (s/r or retard) Tablet tab (40% of the need) 0 PDF created with pdfFactory Pro trial version www.pdffactory.com وﺣدة NATIONAL اﻻﺣﺗﯾﺎج اﻟﻧﮭﺎﺋﻲ اﻟﻣﻼﺣظﺎت اﻟﻘﯾﺎس CODE ﯾﺳﺗﻌﻣل ﻓﻲ ﻣراﻛز اﻟﻌﻧﺎﯾﺔ اﻟﻣرﻛزة واﻟﺗﺧدﯾر ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟرﺋﯾﺳﯾﺔ ﻓﻲ ﺑﻐداد و اﻟﻣﺣﺎﻓظﺎت و ﺑﻛﻣﯾﺎت ﻣﺣدودة. - ﺗﺳﺗﻌﻣل ﻓﻲ ﺣﺎﻻت ھﺑوط ﺿﻐط اﻟدم اﻟﺣﺎد (acute hypotensin) ﺑواﺳطﺔ اﻻرواء اﻟورﯾدي I.V. infusion وﻛذﻟك ﻟﻣﻌﺎﻟﺟﺔ ﺣﺎﻻت ﺗوﻗف اﻟﻘﻠب ﺑواﺳطﺔ amp اﻟزرق اﻟورﯾدي او اﻟزرق اﻟﻣﺑﺎﺷر داﺧل اﻟﻘﻠب rapid - . ( intravennous or intracardiac inj ﺗﺳﺗﻌﻣل اﻟﻣﺎدة ﻓﻲ ﺣﻘل ادوﯾﺔ اﻟﺳﻣوم .- ﺗﺧﻔف اﻟﻣﺎدة ﻗﺑل Norepinephrine Bitartarate / Noradrenaline اﻻﺳﺗﻌﻣﺎل و ﺗﺗﺑﻊ اﻟﺗﻌﻠﯾﻣﺎت ﻓﻲ اﻟﻧﺷرة اﻟﻣرﻓﻘﺔ ﻣﻊ اﻟدواء. acid tartarate 2mg/ml (Ξnoradrenaline base 17466 ﯾؤﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎر اﺳﺗﺧداﻣﮫ ﺿﻣن ﻗواﺋم اﻟﺗﺧدﯾر 01-G00-014 1mg/ml)(2ml amp)I.V. infusion 1G SYMPATHOMIMETIC DRUGS 0 (اﺣﺗﯾﺎج واﺣـــد) Dobutamine (as Hcl)l i.v infusion 250 vial 01-G00-001 mg/vial(12.5 mg/ml 20 ml) 32835 Dobutamine (as Hcl)l i.v infusion inj 250 mg/ amp 0 ﯾﺗم اﻻﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎراﺳﺗﺧداﻣﮫ ﻓﻲ ﻗواﺋم اﻟﺗﺧدﯾر (01-G00-011 Ampoule (12.5 mg/ml 20 ml 107430 ﯾﺗم اﻻﺧذ ﺑﻧظر اﻻﻋﺗﺑﺎراﺳﺗﺧداﻣﮫ ﻓﻲ ﺣﺎﻻت( اﻟﺗﺧدﯾر 01-G00-002 Dopamine Hcl inj 40mg/ml, (5ml) Ampoule amp 0 واﻟﻘﻠﺑﯾﺔ واﻟﺳﻣوم) (اﺣﺗﯾﺎج واﺣـــد) 01-G00-013 Dopamine Hcl 40mg/ml, (5ml) vial vial وﺗﺳﺗﺧدم ﻓﻲ اﻟﻘﻠﺑﯾﺔ اﯾﺿﺎ ﯾﺗم اﻻﺧذ ﺑﻧظر Phenylephrine Hcl 10mg/ml, By s.c. or I.M or 7572 اﻻﻋﺗﺑﺎراﺳﺗﺧداﻣﮫ ﻓﻲ ﻗواﺋم اﻟﺗﺧدﯾر 01-G00-007 by slow I.V or I.V infusion (1ml) Ampoule 1H SCLEROSING AGENTS 0 Ethanolamine oleate 5% Injection 5ml amp ( limited amount) amp 01-H00-001 (limited amount) 674 Drugs used for ductus arteriosus 1I 0 limited) (ﻓﻲ ﻣراﻛز اﻟﻘﻠب اﻟﺗﺧﺻﺻﯾﺔ ﻓﻘط ) , Alprostadil 500mcg/ml in alcohol,for dilution I.V.
Load more

Recommended publications
  • Model Answer
    MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ Important Instructions to examiners: 1) The answers should be examined by key words and not as word-to-word as given in the model answer scheme. 2) The model answer and the answer written by candidate may vary but the examiner may try to assess the understanding level of the candidate. 3) The language errors such as grammatical, spelling errors should not be given more Importance (Not applicable for subject English and Communication Skills. 4) While assessing figures, examiner may give credit for principal components indicated in the figure. The figures drawn by candidate and model answer may vary. The examiner may give credit for anyequivalent figure drawn. 5) Credits may be given step wise for numerical problems. In some cases, the assumed constant values may vary and there may be some difference in the candidate’s answers and model answer. 6) In case of some questions credit may be given by judgement on part of examiner of relevant answer based on candidate’s understanding. 7) For programming language papers, credit may be given to any other program based on equivalent concept. Page no.1/28 MAHARASHTRA STATE BOARD OF TECHNICAL EDUCATION (Autonomous) (ISO/IEC - 27001 - 2005 Certified) MODEL ANSWER WINTER– 18 EXAMINATION Subject Title: PHARMACEUTICAL CHEMISTRY-l Subject Code: 0806 ________________________________________________________________________________________ 1 ANSWER ANY EIGHT OF THE FOLLOWING. 16M (8x2) 1 a) State any four ideal properties of buffer solution. ANY The pH of buffer solution remains constant.
    [Show full text]
  • Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic
    Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic 18F-FDG Activity in the Intestine Jan D. Soyka1, Klaus Strobel1, Patrick Veit-Haibach1, Niklaus G. Schaefer1, Daniel T. Schmid1, Alois Tschopp2, and Thomas F. Hany1 1Department of Nuclear Medicine, University Hospital, Zurich, Switzerland; and 2Department for Biostatistics, University of Zurich, Zurich, Switzerland Our objective was to investigate the use of bowel preparation be- mendations have been made in order to reduce physiologic fore 18F-FDG PET/CT to reduce intestinal 18F-FDG uptake. uptake of 18F-FDG in the intestine or to improve the ability Methods: Sixty-five patients with abdominal neoplasias were to evaluate intestinal structures (5–8). However, no published assigned either to a bowel-preparation group (n 5 26) or to a na- tive group (n 5 39). 18F-FDG activity was measured in the small study has proven that bowel preparation before PET/CT intestine and the colon. Results: In the 26 patients with bowel is beneficial. We therefore conducted a naturally randomized preparation, average maximal standardized uptake value (SUV- and single-blinded study to evaluate the effects of bowel max) was 3.5 in the small intestine and 4.4 in the colon. In the cleansing on intestinal 18F-FDGactivityinPET/CT. 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. 18F-FDG activity im- MATERIALS AND METHODS paired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P 5 0.5). SUV- This prospective, naturally randomized, and single-blinded max in the colon was significantly higher in the bowel-prepara- study was approved by our local ethics committee.
    [Show full text]
  • Assessment Report on Cassia Senna L
    European Medicines Agency Evaluation of Medicines for Human Use London, 27 April 2007 Doc. Ref. EMEA/HMPC/51868/2006 Corr. COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON CASSIA SENNA L. AND CASSIA ANGUSTIFOLIA VAHL, FOLIUM Herbal substance Cassia senna L. (C. acutifolia Delile) [Alexandrian or Khartoum senna] or Cassia angustifolia Vahl [Tinnevelly senna], folium (senna leaf) or a mixture of the two species Herbal preparation dried leaflets, standardised; standardised herbal preparations thereof Pharmaceutical forms Herbal substance for oral preparation Rapporteur Dr C. Werner Assessor Dr B. Merz Superseded 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. Introduction 3 II. Clinical Pharmacology 3 II.1 Pharmacokinetics 3 II.1.1 Phytochemical characterisation 3 II.1.2 Absorption, metabolism and excretion 4 II.1.3 Progress of action 5 II.2 Pharmacodynamics 5 II.2.1 Mode of action 5 • Laxative effect 5 II.2.2 Interactions 7 III. Clinical Efficacy 7 III.1 Dosage 7 III.2 Clinical studies 8 III.2.1 Constipation 8 III.2.2 Irritable bowel syndrome 10 III.2.3 Bowel cleansing 11 III.3 Clinical studies in special populations 15 III.3.1 Use in children 15 III.3.2 Use during pregnancy and lactation 16 III.4 Traditional use 17 IV.
    [Show full text]
  • Randomized Controlled Trial of a Natural Food-Based Fiber Solution to Prevent Constipation in Postoperative Spine Fusion Patients
    1.5 ANCC Contact Hours Randomized Controlled Trial of a Natural Food-Based Fiber Solution to Prevent Constipation in Postoperative Spine Fusion Patients Deborah Wittig-Wells ▼ Pam Sapp ▼ Melinda Higgins ▼ Erica Davis ▼ Jessica Carter ▼ Ani Jacob BACKGROUND: Constipation after orthopaedic surgery orthopaedic surgery occurs frequently, likely due to a occurs frequently, likely due to a combination of high levels combination of high levels of opioid medications for of opioid medications for severe pain management and severe pain management and mobility limitations after mobility limitations after surgery. It can result in serious surgery (Ross-Adjie, Monterosso, & Bulsara, 2015). complications, increased cost, and patient discomfort. Although constipation may be considered mild and PURPOSE: This study evaluated a natural food-based fiber self-limiting, it can increase the length of hospital stay and increase financial burdens for both the patient and the in- solution to prevent constipation in postoperative orthopae- stitution. Constipation may lead to significant morbidity dic patients. and, in rare cases, death (Davies et al., 2008). Reported METHODS: A posttest control group-randomized study rates of constipation in postoperative orthopaedic patients design was used. Dependent variables were presence of are between 40% and 60% (Park, Kim, Yun, & Yu, 2016; postoperative constipation, time to first bowel movement Ross-Adjie et al., 2015). Because constipation frequently (BM), and total number of postoperative BMs. Descriptive occurs in the postoperative orthopaedic population, pre- statistics, Student’s t tests, and Mann–Whitney nonparamet- vention and treatment of constipation are essential. ric 2-group tests with chi-square analysis were used. Level Dietary fiber is thought to improve gastrointestinal of significance for all tests was p < .05.
    [Show full text]
  • WO 2017/066488 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/066488 A l 2 0 April 2017 (20.04.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/5415 (2006.01) A61P 1/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/0569 10 HN, HR, HU, ID, IL, EST, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 October 2016 (13.10.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/240,965 13 October 2015 (13. 10.2015) US (84) Designated States (unless otherwise indicated, for every 62/300,014 25 February 2016 (25.02.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: CHARLESTON LABORATORIES, INC.
    [Show full text]
  • E42 Appendix 1 (Part 1 of 2): Categorization of Medications
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (Part 1 of 2): Categorization of medications. Class and Type of Medication Specific Drugs Psychotropic Antiparkinsonian Benztropine, carbidopa/levodopa, levodopa/benserazide, pramipexole, procyclidine Hypnotic Zopiclone Antipsychotic (typical or atypical) Risperidone, olanzapine, quetiapine, haloperidol, perphenazine, loxapine, clozapine, methotrimeprazine Antidepressant Sertraline, trazodone, mirtazapine, citalopram, escitalopram, duloxetine Benzodiazepine Lorazepam, clonazepam, oxazepam Anticonvulsant Pregabalin, levetiracetam, phenytoin, valproic acid, gabapentin, divalproex, topiramate Cholinesterase inhibitor Donepezil Anticholinergic Atropine CNS stimulant Methylphenidate Cardiovascular Diuretic Furosemide, metolazone, spironolactone, indapamide, acetazolamide, hydrochlorothiazide Antilipemic Rosuvastatin, atorvastatin Antihypertensive Amlodipine, diltiazem, hydralazine ␤-Blocker Bisoprolol, metoprolol, carvedilol, propranolol ACE inhibitor Lisinopril, ramipril, enalapril, perindopril, fosinopril Angiotensin II receptor blocker Olmesartan, irbesartan, valsartan, candesartan Antianginal Nitroglycerin Hematologic Anticoagulant Enoxaparin, heparin, apixaban, rivaroxaban, warfarin Platelet inhibitor Acetylsalicylic acid, clopidogrel Anemia therapy Ferrous gluconate, ferrous fumarate Endocrine Hormone replacement Levothyroxine,
    [Show full text]
  • Medical Supplement
    MEDICAL SUPPLEMENT Name _______________________________________ Date ______________________________ Are you presently being treated for medical problems? ⃝ Yes ⃝ No If yes, for what problem and who is treating you?__________________________________________________ ___________________________________________________________________________________________ When was your last physical examination?______________________________________________________________ Where and by whom?_________________________________________________________________________ List all medications you are currently taking, including over the counter and herbal/natural preparations: Medication Dosage Why do you take it? Who prescribes? 1 1000 Darrington Drive, Suite 204, Cary, North Carolina 27513 | (P) 919.338.5620 | (F) 919.336.4519 | [email protected] MEDICAL SUPPLEMENT Do you have any drug, food, or environmental allergies? __________________________________________________________________________________________________ __________________________________________________________________________________________________ Have you had any bad drug reactions? Please describe. __________________________________________________________________________________________________ __________________________________________________________________________________________________ Please list any surgeries: Date ___________________Surgery For ___________________________________________ Date ___________________Surgery For ___________________________________________ Date ___________________Surgery
    [Show full text]
  • Melanosis Coli
    DOI: 10.31662/jmaj.2021-0031 https://www.jmaj.jp/ Images Melanosis Coli Akira Kuriyama Key Words: melanosis, constipation, laxatives, anthraquinone A 75-year-old man with a 23-year history of poorly controlled Informed Consent type 2 diabetes mellitus presented with chronic constipation. Written informed consent was obtained from the patient to Colonoscopy showed heavily pigmented mucosa, resembling publish this case report including the accompanying images. leopard skin, from the cecum through the ascending colon (Figure 1). The patient had been using senna glycoside for the References last 7 years, which supported a diagnosis of melanosis coli. A multicenter observational study with patients who had 1. Wang S, Wang Z, Peng L, et al. Gender, age, and concomitant undergone colonoscopy suggested that the prevalence of mela- diseases of melanosis coli in China: a multicenter study of 6,090 nosis coli is approximately 1.8% (1). Melanosis coli is associated cases. PeerJ. 2018;6:e4483. with the chronic use of laxatives, particularly those containing 2. Byers RJ, Marsh P, Parkinson D, et al. Melanosis coli is anthraquinones, such as senna, rhubarb, and cascara. It can associated with an increase in colonic epithelial apoptosis and develop within a few months of using anthraquinone-contain- not with laxative use. Histopathology. 1997;30(2):160-4. ing laxatives. Anthraquinones cause direct injury to and apop- 3. Biernacka-Wawrzonek D, Stepka M, Tomaszewska A, et al. tosis of the colonic epithelial cells, resulting in lipofuscin dep- Melanosis coli in patients with colon cancer. Przeglad osition in the macrophages of the lamina propria (2), which is gastroenterologiczny.
    [Show full text]
  • National Master List of Drugs and Lab Reagents
    ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 2539500 02-01-00002 Digitoxin 100mcg Tablet 2397000 02-01-00003 Digoxin 125 mcg Tablet 2622000 02-01-00004 Digoxin 250 mcg Tablet 44165500 02-01-00005 Digoxin 50mcg /ml PG Elixir 800000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50000000 02-01-00009 Bumetanide 1 mg Tablet 1369000 02-01-00010 Chlorthalidone 50mg Tablet 6360500 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 9437000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800000 02-01-00014 Frusemide 40mg Tablet 78372000 02-01-00015 Frusemide 500mg Scored Tablet 800000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800000 02-01-00017 Frusemide 4mg/ml Oral Solution 800000 02-01-00018 Frusemide 8mg/ml oral Solution 800000 02-01-00019 Hydrochlorothiazide 25mg Tablet 3173000 02-01-00020 Hydrochlorothiazide 50mg Tablet 3033500 02-01-00021 Indapamide 2.5mg Tablet 800000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800000 02-01-00023 Spironolactone 25mg Tablet 8426000 02-01-00024 Spironolactone 100mg Tablet 5829500 02-01-00025 Xipamide 20mg Tablet 800000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800000 02-01-00027 Acebutolol 200mg Tablet 800000 02-01-00028 Atenolol 100mg Tablet 120000000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 48893000 02-01-00030 Atenolol 25mg Tablet 8628500 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800000 02-01-00033 Carvedilol 6.25mg Tablet 3279500 02-01-00034 Carvedilol 12.5mg Tablet 2228500 02-01-00035 Carvedilol 25mg Tablet 2650000 02-01-00036 Esmolol Hcl 10mg/ml I.V.
    [Show full text]
  • A Case Report of Delirium Induced by Herbal Laxative Senna
    International Journal of Health Sciences and Research DOI: https://doi.org/10.52403/ijhsr.20210636 Vol.11; Issue: 6; June 2021 Website: www.ijhsr.org Case Report ISSN: 2249-9571 A Case Report of Delirium Induced by Herbal Laxative Senna Nimitha K J1, Porimita Chutia2, Pooja Misal3, Bhupendra Singh4 1,2,3 Senior Resident, 4Additional Professor, Department of Geriatric Mental Health, King George’s Medical University, Lucknow, India Corresponding Author: Nimitha K J ABSTRACT Constipation is one major complaint in elderly population. It may be due to physiological and anatomical reasons of aging, but it can be also due chronic medical and mental illnesses and due to use of multiple medications. Constipation itself is a precipitating factor for delirium. Drugs used for constipation can also be the culprit. A 64-year-old female who had a history of hypertension and chronic constipation presented with symptoms of confused and altered behavior, decreased oral intake, decreased sleep. On history taking it was known that she was using Herbal medication containing senna glycoside and other compounds since 8-9months. On examination she had signs of dehydration, disoriented and attention was impaired. On investigation her serum sodium was 122.6 mmol/ and other investigations were within normal limits. She was diagnosed as a case of Delirium according to ICD-10 criteria. Her dehydration was corrected by giving intravenous fluids and serum sodium level was corrected using salt capsules 2 tablets thrice daily. For disturbed sleep she was prescribed Tab Melatonin 10mg at bedtime and constipation was treated with per rectal enema and syrup lactulose 30ml at bedtime.
    [Show full text]
  • WO 2018/013871 Al 18 January 2018 (18.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/013871 Al 18 January 2018 (18.01.2018) W !P O PCT (51) International Patent Classification: Published: A61K 31/715 (2006.01) A61P 43/00 (2006.01) — with international search report (Art. 21(3)) A61K 9/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/042022 amendments (Rule 48.2(h)) (22) International Filing Date: 13 July 2017 (13.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/361,998 13 July 2016 (13.07.2016) US (71) Applicant: KALEIDO BIOSCIENCES, INC. [US/US]; 47 Moulton St, Cambridge, MA 02138 (US). (72) Inventors: VON MALTZAHN, Geoffrey, A.; 42 Myrtle St Apt Bl, Somerville, MA 02145 (US). RUBENS, Ja¬ cob, Rosenblum; 177 Hancock St., Cambridge, MA 02139 (US). (74) Agent: COLLAZO, Diana, M. et al; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Clozapine-Induced GI Hypomotility: from Constipation to Bowel Obstruction
    Pearls Clozapine-induced GI hypomotility: From constipation to bowel obstruction Andrew Cruz, MD, and Oliver Freudenreich, MD Dr. Cruz is a PGY-2 resident, MGH/ Table McLean Adult Psychiatry Residency atients who are treated with clozap- Program, and Dr. Freudenreich ine—a second-generation antipsy- Bowel regimen for chronic is Co-Director, Schizophrenia chotic approved for treatment-resistant constipation Clinical and Research Program, P Massachusetts General Hospital, schizophrenia—require monitoring for seri- Stool softener (daily) Boston, Massachusetts. ous adverse effects. Many of these adverse Docusate sodium 100 mg twice daily Disclosures effects, such as agranulocytosis or seizures, Stimulant laxative (weekly and as needed) The authors report no financial relationships with any company are familiar to clinicians; however, gastro- Bisacodyl, 5 to 15 mg/d, as needed whose products are mentioned in intestinal (GI) hypomotility is not always Senna glycoside, 15 mg/d, as needed this article, or with manufacturers of competing products. recognized as a potentially serious adverse effect, even though it is one of the most common causes for hospital admission.1 Its Staff who care for patients taking clozapine manifestations range from being relatively who live in a supervised setting should be benign (nausea, vomiting, constipation) to educated about the relevance of a patient’s potentially severe (fecal impaction) or even changing bowel habits or GI complaints. life-threatening (bowel obstruction, ileus, Also, teach patients about simple lifestyle toxic megacolon).2 modifications they can make to counteract GI hypomotility is caused by clozapine’s constipation, including increased physical strong anticholinergic properties, which activity, adequate hydration, and consum- lead to slowed smooth muscle contrac- ing a fiber-rich diet.
    [Show full text]